April 28, 2020 / 9:33 PM / a month ago

BRIEF-Inovio And Geneone Life Science Report Positive Phase 1/2A Clinical Data With Dna Vaccine Ino-4700 For Mers Coronavirus

April 28 (Reuters) - Inovio Pharmaceuticals Inc:

* INOVIO AND GENEONE LIFE SCIENCE REPORT POSITIVE PHASE 1/2A CLINICAL DATA WITH DNA VACCINE INO-4700 FOR MERS CORONAVIRUS AT THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT) CONFERENCE

* INOVIO PHARMACEUTICALS INC - INO-4700 (GLS-5300) DNA VACCINE DEMONSTRATES 100% BINDING AND 92% NEUTRALIZING ANTIBODY RESPONSES AGAINST MERS-COV

* INOVIO - INO-4800 DNA VACCINE FOR COVID-19 CURRENTLY IN PHASE 1 TRIAL USES IDENTICAL STRATEGY TARGETING SPIKE PROTEIN, CELLECTRA INTRADERMAL DELIVERY

* INOVIO - PLANNING TO ADVANCE INO-4700 INTO A PHASE 2 CLINICAL TRIAL IN MIDDLE EAST WITH FUNDING BY COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below